IRMD Iradimed Corp

Price (delayed)

$89.83

Market cap

$1.15B

P/E Ratio

49.36

Dividend/share

$1.27

EPS

$1.82

Enterprise value

$1.09B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 94

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, ...

Highlights
Iradimed's quick ratio has increased by 37% from the previous quarter and by 9% YoY
The company's revenue rose by 11% YoY
IRMD's price to earnings (P/E) is 24% higher than its 5-year quarterly average of 39.7 but 2.5% lower than its last 4 quarters average of 50.5
Iradimed's net income has increased by 12% YoY but it has decreased by 2.4% from the previous quarter

Key stats

What are the main financial stats of IRMD

IRMD stock price

How has the Iradimed stock price performed over time
Intraday
0.2%
1 week
5.1%
1 month
8.85%
1 year
22.65%
YTD
-7.66%
QTD
4.19%

Financial performance

How have Iradimed's revenue and profit performed over time
Revenue
$86.34M
Gross profit
$65.5M
Operating income
$27.56M
Net income
$23.05M
Gross margin
75.9%
Net margin
26.7%
The company's operating income rose by 16% YoY
Iradimed's net income has increased by 12% YoY but it has decreased by 2.4% from the previous quarter
The company's revenue rose by 11% YoY
The gross profit is up by 10% YoY

Price vs fundamentals

How does IRMD's price correlate with its fundamentals

Growth

What is Iradimed's growth rate over time

Valuation

What is Iradimed stock price valuation
P/E
49.36
P/B
11.29
P/S
13.3
EV/EBIT
36.63
EV/EBITDA
34.73
EV/Sales
12.62
IRMD's price to earnings (P/E) is 24% higher than its 5-year quarterly average of 39.7 but 2.5% lower than its last 4 quarters average of 50.5
Iradimed's EPS has increased by 12% YoY but it has decreased by 2.2% QoQ
The price to book (P/B) is 36% higher than the 5-year quarterly average of 8.3 but 3.8% lower than the last 4 quarters average of 11.7
Iradimed's equity has increased by 8% YoY and by 3.3% QoQ
The price to sales (P/S) is 30% higher than the 5-year quarterly average of 10.2 but 2.4% lower than the last 4 quarters average of 13.6
The company's revenue rose by 11% YoY

Efficiency

How efficient is Iradimed business performance
Iradimed's return on equity has decreased by 4.1% QoQ
The company's return on assets fell by 4.2% QoQ
Iradimed's return on invested capital has decreased by 2.5% QoQ and by 2.1% YoY
Iradimed's return on sales has increased by 3% YoY

Dividends

What is IRMD's dividend history
DPS
$1.27
Dividend yield
1.41%
Payout ratio
69.8%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Iradimed financials performed over time
Iradimed's quick ratio has increased by 37% from the previous quarter and by 9% YoY
The current ratio is up by 33% since the previous quarter and by 8% year-on-year
The company's debt is 100% lower than its equity
Iradimed's equity has increased by 8% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.